...

CCO Independent Conference Coverage


conference image

2009 Annual Meeting of the AACR-CTRC San Antonio Breast Cancer Symposium*

December 9-13, 2009 | San Antonio, Texas

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.


Choose from 3 tracks of coverage (mouse over track for more info)

Expert Highlights

Nicholas J. Robert, MD headshot Nicholas J. Robert, MD, reviews highlights from the 32nd Annual San Antonio Breast Cancer Symposium focused on early-stage breast cancer including HER2-positive breast cancer, endocrine therapy management, biology of tumors, and prevention strategies. (10 minutes) Download Audio
Kathy D. Miller, MD headshot Kathy D. Miller, MD, reviews highlights from the 32nd Annual San Antonio Breast Cancer Symposium regarding treatment of patients with metastatic breast cancer including the use of RANK ligand inhibitors and antiangiogenic agents, as well as updates in the treatment of HER2-positive disease. (6 minutes) Download Audio
Daniel F. Hayes, MD headshot Daniel F. Hayes, MD, reviews highlights from the 32nd Annual San Antonio Breast Cancer Symposium regarding studies demonstrating the utility of prognostic and predictive tools to help guide treatment choices. (6 minutes) Download Audio

Disclosures – Audio Expert Highlights

Daniel F. Hayes, MD, has disclosed that he has owned stock in Oncimmune; has served as a consultant for Compendia Bioscience, Curalogic, DNAR, and Incyte Genomics; and has received honoraria from GlaxoSmithKline, Pfizer, and sanofi-aventis; and has served as a principal or coprincipal investigator for AstraZeneca, GlaxoSmithKline, Novartis, Pfizer, Veridex, and Wyeth-Ayerst.

Kathy D. Miller, MD, has disclosed that she has received contracted research support from Amgen and Pfizer.

Nicholas J. Robert, MD, has disclosed that he has received consulting fees from Novartis, Roche, sanofi-aventis; fees for non-CME services from Roche and sanofi-aventis; and contracted research fees from Roche and Genentech.

CCO Slidesets

Early Breast Cancer: Highlights

Download the Slideset


Download slides on the most clinically-relevant data in early breast cancer presented at the 2009 Breast Cancer Annual meeting.


Format: Microsoft PowerPoint (.ppt) | File size: 1.28 MB | Date posted: 1/11/2010


Metastatic Breast Cancer: Highlights

Download the Slideset


Review highlights of clinically relevant studies in metastatic breast cancer presented at the 2009 Breast Cancer Annual Meeting.


Format: Microsoft PowerPoint (.ppt) | File size: 850 KB | Date posted: 1/13/2010


Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Capsule Summary:

HER2 Positivity a Risk Factor for Recurrence in ER-Positive Early-Stage Breast Cancer

HER2-positive patients at significantly higher risk of recurrence within the first 2.5 years after being diagnosed with early-stage breast cancer.

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES